Inactive Instrument

All News Millendo Therapeutics

Equities

MLND

US60040X1037

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	30/22/30	CI
Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer	30/21/30	CI
TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	24/21/24	AQ
Tempest Therapeutics : BUSINESS (Form 8-K)	17/21/17	PU
TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	17/21/17	AQ
Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	12/21/12	AQ
TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	12/21/12	AQ
Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	09/21/09	AQ
TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	08/21/08	AQ
Millendo Therapeutics : Amendment to Current Report (SEC Filing - 8-K/A)	02/21/02	PU
Tempest Therapeutics : MILLENDO THERAPEUTICS, INC. Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K/A)	02/21/02	AQ
Millendo Therapeutics : Tempest Closes Merger with Millendo and Completes PIPE Financing (Form 8-K)	29/21/29	PU
Reverse Split: 1 of 15	28/21/28	FA
Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index	25/21/25	CI
Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	25/21/25	CI
Millendo Therapeutics : Tempest and Millendo Announce Stockholder Approval of Merger (Form 8-K)	23/21/23	PU
MILLENDO THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	23/21/23	AQ
Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	23/21/23	MT
MILLENDO THERAPEUTICS, INC. : Other Events (form 8-K)	12/21/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Millendo Therapeutics

Equities

MLND

US60040X1037

All News

Filters